High density lipoprotein future or investigational therapies: Difference between revisions
No edit summary |
|||
| Line 24: | Line 24: | ||
==De-lipidated HDL Infusions== | ==De-lipidated HDL Infusions== | ||
==HDL | ==HDL Mimetics== | ||
===ApoA-I Mimetic Peptides | ===ApoA-I Mimetic Peptides=== | ||
* D-4F and L-4F | * D-4F and L-4F | ||
===ATI-5261 Synthetic Peptide=== | ===ATI-5261 Synthetic Peptide=== | ||
===Endothelial Lipase Inhibitors=== | ===Endothelial Lipase Inhibitors=== | ||
===LCAT Modulators=== | ===LCAT Modulators=== | ||
==Endocannabinoid Receptor Blockers== | ==Endocannabinoid Receptor Blockers== | ||
==ApoA-I Upregulators== | ==ApoA-I Upregulators== | ||
Revision as of 19:38, 19 September 2013
|
High Density Lipoprotein Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Clinical Trials |
|
Case Studies |
|
High density lipoprotein future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of High density lipoprotein future or investigational therapies |
|
FDA on High density lipoprotein future or investigational therapies |
|
CDC on High density lipoprotein future or investigational therapies |
|
High density lipoprotein future or investigational therapies in the news |
|
Blogs on High density lipoprotein future or investigational therapies |
|
Risk calculators and risk factors for High density lipoprotein future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aarti Narayan, M.B.B.S [2]; Raviteja Guddeti, M.B.B.S. [3]
Overview
The Need
The importance of increasing serum levels and functionality of HDL-C in lowering residual cardiovascular risks in patients with acute coronary syndromes cannot be over-emphasized. First of all, some recent studies reported failures of orally active medications that increase serum levels of HDL-C to potentially improve cardiovascular outcomes, such as niacin in the AIM-HIGH Trial. This have shifted the focus of researchers to other targets of HDL therapy aimed at increasing the serum levels of HDL as well as its functionality i.e., cellular cholesterol efflux and HDL-mediated reverse cholesterol transport mechanisms. Secondly, since the available oral medications elevate HDL over weeks to months, there is the need for medications to improve outcomes during acute vascular events.
Cholesterol Ester Transfer Protein (CETP) Inhibition
Torcetrapib
Dalcetrapib
Anacetrapib
Evacetrapib
Direct Infusion of Apo A-I
This involves the reconstituted and the recombinant preparations.
Potential Therapeutic Considerations
Clinical Significance
ApoA-1 Milano
CSL-112
CER-001
De-lipidated HDL Infusions
HDL Mimetics
ApoA-I Mimetic Peptides
- D-4F and L-4F